Table 1 Clinical and sociodemographic characteristics of the PWH included in the study.

Parameters^a	MVC-Initiation (n = 12)	non-MVC-Initiation (n = 22)	MVC-switch (n = 9)	Statistics ^b
Duration of ART (weeks)	89 [72–117]	87 [72–114]	98 [73–128]	p = 0.867
Sex				p = 0.303
Male	11 (92%)	21 (96%)	7 (78%)
Female	1 (8%)	1 (4%)	2 (22%)
Age (years)	36.8 [26.7–42.2]	32.5 [23.8–41.3]	46.2 [32.7–58.8]	p = 0.008
Transmission				p = 0.141
MSM	10 (83%)	16 (73%)	4 (44%)
Heterosexual	1 (8%)	3 (13%)	2 (22%)
IDU	0 (0%)	0 (0%)	2 (22%)
Unknown/Other	1 (8%)	3 (13%)	1 (12%)
Region of origin				p = 0.446
Spain	8 (67%)	16 (73%)	9 (100%)
Latin America	3 (25%)	4 (18%)	0 (0%)
Other/Unknown	1 (8%)	2 (9%)	0 (0%)
CD4 counts (cells/mm³)	96.0 [35.3–213.5]	367.0 [277.5–584.5]	279.0 [164.0–574.0]	p = 0.007
Viral load (HIV RNA copies/ mL)	661,150 [127,947–2,075,000]	49,010 [16,539–178,553]	< 20 [< 20–31]	p = 0.001
Undetectable viral load post-ART				p = 0.725
Yes	9 (75%)	18 (86%)	7 (78%)
No	3 (25%)	3 (14%)	2 (22%)
Initial ART regimen				p = 0.101
NNRTI-based	5 (42%)	13 (59%)	4 (44%)
INTI-based	4 (33%)	5 (23%)	0 (0%)
PI-based	3 (25%)	3 (14%)	5 (56%)

^aDuration of ART, CD4 counts, viral load and age are expressed as median and IQRs [interquartile ranges]. Duration of ART, CD4 counts, viral load and age were considered from ART initiation in MVC-Initiation and non-MVC-Initiation groups, or from the inclusion of MVC in the treatment regimen in the MVC-switch. Undetectable viral load post-ART (< 50 copies HIV-RNA/mL) was considered between 48 to 96 weeks after ART initiation. ART regimen was considered upon treatment initiation. NNRTI: non-nucleoside reverse transcription inhibitors; INTI: Integrase Inhibitors; PI: Protease Inhibitor.
^bStatistics: Duration of ART, CD4 counts, viral load and age were analyzed with ANOVA test; transmission, sex, region of origin, initial ART regimen and undetectable viral load post-ART were analyzed with the Chi-square test.

Search